Zealand Pharma (ZLDPF) announced an agreement with DCAI, an AI infrastructure company which operates Gefion, Denmark’s supercomputer, for drug discovery. The company said, working with DCAI, Zealand Pharma will be able to integrate enterprise-scale artificial intelligence into its drug discovery and development workflows, generating proprietary insights that further enhance the quality and efficiency of medicine creation.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma price target raised to DKK 450 from DKK 430 at Deutsche Bank
- Zealand Pharma to pay $20M upfront in OTR Therapeutics license agreement
- Zealand Pharma price target lowered to DKK 1,000 from DKK 1,050 at JPMorgan
- Zealand Pharma price target lowered to DKK 825 from DKK 850 at Berenberg
- Zealand Pharma’s Earnings Call: Strong Growth Amid Challenges